Bacterial Infections OralNCT05475444
PLGA Nanoparticles Entrapping Ciprofloxacin to Treat E-Fecalis Infections in Endodontics
A study testing Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels and Ciprofloxacin paste and solution in people with Bacterial Infections Oral, run by British University In Egypt at 1 site in Egypt.
Trial summary
PLGA nanoparticles coated with Chitosan polymer were prepared and then incorporated in In -situ gel to be injected to root canals of patients suffered from bacterial infection of their endodontics. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bacterial Infections Oral
- What is being tested?
- Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels and Ciprofloxacin paste and solution
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Mar 2020to 15 Mar 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Root canal filled single rooted teeth with post treatment disease manifested by one or more of the following signs and symptoms:
- History of recurrent acute and/or chronic periapical abscess
- Pain on palpation and/or percussion at least after one month of previous procedure
- Radiographic evidence of bone loss either as a new developing lesion or an increase in the size of a pre-existing one.
Who cannot join
- Teeth that were badly broken down indicated for extraction or with difficult isolation
- Immuno-compromised patients.
- Patients with history of taking antibiotics orally.
- Periodontally affected teeth.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Mona Arafa
Cairo, El Sherouk City , Suez Desert Road , Cairo - P.O. Box 43, 11837
About this study
Official title: Modified Surface of PLGA Nanoparticles in Smart Hydrogel: A Randomized Clinical Trial to Establish an Advanced Strategy Against Antibiotic Resistant Infections in Endodontics
PLGA nanoparticles coated with Chitosan polymer were prepared and then incorporated in In -situ gel to be injected to root canals of patients suffered from bacterial infection of their endodontics.
Read the detailed description
The Clinical procedures:
- First visit Treatment plan was discussed with the patients and their acceptance to participate in the study was obtained through an informed consent. Coronal restorations and any carious decay were removed, teeth properly restored then rubber dam was applied for isolation. An access cavity was prepared using an appropriate size bur (Bur #3, Veterinary dental equipment, UK) , and the tooth surface was disinfected before entering the root canals using 2.5% sodium hypochlorite, then its effect was inhibited using 5% sodium thiosulphate. The old gutta percha was removed from the coronal two thirds of the root canal using bur #3 without using any solvent. Sterile saline was used for irrigation. Patency was obtained using manual k files #15 (and #10, tooth length was determined using an electronic apex locator (Electronic apex locator J Morita Root ZX, Morita Corporation, Japan). The remaining gutta percha was removed using gradually increasing sizes of manual k files (K- files, Mani, Japan) . Scrubbing of the walls using manual files was done to soak the irrigant (sterile saline) with parts of the bacterial film on the canal walls. Sterile paper point equivalent to the size of largest file reaching the working length was placed for one minute in the canal and located one millimeter away from the tooth length, this represented the first sample for bacteriological assessment (S1) then paper point was placed in 1ml sterile medium. Complete cleaning and shaping of the canal was done using 15 ml of 2.5% sodium hypchlorite as an irrigant with a side vented needle of gauge 27, placed one millimeter from the working length and manual k type files, the master apical file was determined according to each case, where its size was increased 3 times more than the initial file with obtained white dentine chips as well. After complete cleaning and shaping, the action of sodium hypochlorite was inhibited by using 10 ml of 5% sodium thiosulphate. Sodium thiosulphate was flushed from the canal using 5 ml sterile saline. A sterile paper point equivalent to the size of master apical file was placed for one minute in the canal, one millimeter away from the working length to soak the fluid and this represented the second sample for bacteriological assessment (S2), afterwards, paper point is placed in 1ml sterile medium, then the patients were randomly allocated according to the use of an intracanal medications to the five groups for 7 days. Finally, a cotton pellet and temporary filling (Orafill-G) was applied under complete aseptic conditions
- Second visit
- Assessment of the clinical signs and symptoms was done.
- Clinical criteria for healing:
- No pain with percussion 2. No pain with palpation 3. Tooth asymptomatic and functional If the patient showed these clinical findings, root canals were obturated. If the patient had all or one of them, cleaning, shaping and medication steps were repeated and the patient re-scheduled for another visit after 7 days. If the patient was asymptomatic and the tooth was functional, then a temporary filling was removed under rubber dam isolation. Twenty ml of sterile saline was used to remove the intracanal medicaments until it got out clear from the canal then sterile paper point was placed in the canal one millimeter away from the working length to take the last sample (S3), paper point was placed in 1ml sterile medium, finally master cone adjustment and obturation were done.
These sterile paper points with three samples (S1, S2, S3) were placed separately in sterile falcon tubes, labeled according to the type of medication and the order of the sample. One ml of sterile tryptic soy broth (TSB) supplemented with 0.5% glucose (TSBG) was added to each tube , then tubes were transferred to the microbiology lab within 2-3 hours from sampling procedure in an ice box 4.Microbiological evaluation All microbiological steps were performed in the vicinity of a trilaminar flow cabinet to avoid air contamination of the samples.
- Total percentage of bacterial reduction: A total of 100 μl from each sample containing (4mg) drug in addition to Ca (OH)2 paste and (4mg) CIP past were aspirated using a sterile micropipette from each tube. A sterile inoculum was used to add samples to the brain heart media. The samples were labeled according to the groups of medication and incubated for 24 hours at 37 ºC. After incubation, the total number of bacterial counts was estimated
- Conditions
- Bacterial Infections Oral
- Being tested
- Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels, Ciprofloxacin paste and solution
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gelsDevice
Also called Chitosan Coated PLGA nanoparticles, PLGA nanoparticles as smart gels
antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
Ciprofloxacin paste and solutionDevice
Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
| Study group | Role | What they receive |
|---|---|---|
| Paste and solution of ciprofloxacin as Conventional Treatment | Experimental | Paste and solution of ciprofloxacin as conventional dosage forms and drugs used to treat endodontics infections. For ciprofloxacin solution is used once daily while the paste form used weekly. Receives: Device: Ciprofloxacin paste and solution |
| Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel | Experimental | Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel dosage forms treat endodontics infections Receives: Device: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determination of Bacterial count by counting bacterial colonies of the sample
Bacterial count was expected to be decreased by counting bacterial colonies of the sample after treatment and comparing with control without treatment
Measured: One week
Secondary outcomes (1)
Determination of the Biofilm inhibition using crystal violet and microplate reader
Biofilm is to be inhibited and being small by using of stains crystal violet as marker, in order to more accurately identify cells of interest and distinguish from culture debris.
Measured: one week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2022
- Study start1 Mar 2020
- Primary completion8 Mar 2020
- Study completion15 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bacterial Infections OralStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- * Group I (negative control group): Root canals were not treated after cleaning and shaping. * Group II (positive control group): Root canals were treated with calcium hydroxide paste * Group III: Root canals were treated with CIP paste conventionally used by the dentist which was formed by mixing CIP with saline to form a paste. * Group IV: Root canals were treated with (F1) which is the prepared in-situ gel formulation containing CIP loaded chitosan coated PLGA nanoparticles. * Group V: Root canals were treated with (F2) which is the prepared in-situ gel containing ciprofloxacin hydrochloride.
- Masking
- None (open label)
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- British University In Egypt
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mona Gamal Mohamed Afifi Arafa, British University In Egypt
- Investigators
- Mona Arafa, Professor, Principal investigator, British University In Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05475444
- Sponsor's protocol ID
- 1643
- Status last verified
- Jul 2022
- First submitted
- 6 Feb 2021
- Last updated
- 27 Jul 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modified Surface of PLGA Nanoparticles in Smart Hydrogel: A Randomized Clinical Trial to Establish an Advanced Strategy Against Antibiotic Resistant Infections in Endodontics
- ClinicalTrials.gov ID
- NCT05475444
- Acronym / sponsor ID
- 1643
- Conditions
- Bacterial Infections Oral
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- British University In EgyptUniversity, hospital or other
- Study start
- 1 Mar 2020 (actual)
- Primary completion
- 8 Mar 2020 (actual)
- Study completion
- 15 Mar 2020 (actual)
- First posted
- 27 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PLGA nanoparticles coated with Chitosan polymer were prepared and then incorporated in In -situ gel to be injected to root canals of patients suffered from bacterial infection of their endodontics.
Detailed description
The Clinical procedures:
- First visit Treatment plan was discussed with the patients and their acceptance to participate in the study was obtained through an informed consent. Coronal restorations and any carious decay were removed, teeth properly restored then rubber dam was applied for isolation. An access cavity was prepared using an appropriate size bur (Bur #3, Veterinary dental equipment, UK) , and the tooth surface was disinfected before entering the root canals using 2.5% sodium hypochlorite, then its effect was inhibited using 5% sodium thiosulphate. The old gutta percha was removed from the coronal two thirds of the root canal using bur #3 without using any solvent. Sterile saline was used for irrigation. Patency was obtained using manual k files #15 (and #10, tooth length was determined using an electronic apex locator (Electronic apex locator J Morita Root ZX, Morita Corporation, Japan). The remaining gutta percha was removed using gradually increasing sizes of manual k files (K- files, Mani, Japan) . Scrubbing of the walls using manual files was done to soak the irrigant (sterile saline) with parts of the bacterial film on the canal walls. Sterile paper point equivalent to the size of largest file reaching the working length was placed for one minute in the canal and located one millimeter away from the tooth length, this represented the first sample for bacteriological assessment (S1) then paper point was placed in 1ml sterile medium. Complete cleaning and shaping of the canal was done using 15 ml of 2.5% sodium hypchlorite as an irrigant with a side vented needle of gauge 27, placed one millimeter from the working length and manual k type files, the master apical file was determined according to each case, where its size was increased 3 times more than the initial file with obtained white dentine chips as well. After complete cleaning and shaping, the action of sodium hypochlorite was inhibited by using 10 ml of 5% sodium thiosulphate. Sodium thiosulphate was flushed from the canal using 5 ml sterile saline. A sterile paper point equivalent to the size of master apical file was placed for one minute in the canal, one millimeter away from the working length to soak the fluid and this represented the second sample for bacteriological assessment (S2), afterwards, paper point is placed in 1ml sterile medium, then the patients were randomly allocated according to the use of an intracanal medications to the five groups for 7 days. Finally, a cotton pellet and temporary filling (Orafill-G) was applied under complete aseptic conditions
- Second visit
- Assessment of the clinical signs and symptoms was done.
- Clinical criteria for healing:
- No pain with percussion 2. No pain with palpation 3. Tooth asymptomatic and functional If the patient showed these clinical findings, root canals were obturated. If the patient had all or one of them, cleaning, shaping and medication steps were repeated and the patient re-scheduled for another visit after 7 days. If the patient was asymptomatic and the tooth was functional, then a temporary filling was removed under rubber dam isolation. Twenty ml of sterile saline was used to remove the intracanal medicaments until it got out clear from the canal then sterile paper point was placed in the canal one millimeter away from the working length to take the last sample (S3), paper point was placed in 1ml sterile medium, finally master cone adjustment and obturation were done.
These sterile paper points with three samples (S1, S2, S3) were placed separately in sterile falcon tubes, labeled according to the type of medication and the order of the sample. One ml of sterile tryptic soy broth (TSB) supplemented with 0.5% glucose (TSBG) was added to each tube , then tubes were transferred to the microbiology lab within 2-3 hours from sampling procedure in an ice box 4.Microbiological evaluation All microbiological steps were performed in the vicinity of a trilaminar flow cabinet to avoid air contamination of the samples.
- Total percentage of bacterial reduction: A total of 100 μl from each sample containing (4mg) drug in addition to Ca (OH)2 paste and (4mg) CIP past were aspirated using a sterile micropipette from each tube. A sterile inoculum was used to add samples to the brain heart media. The samples were labeled according to the groups of medication and incubated for 24 hours at 37 ºC. After incubation, the total number of bacterial counts was estimated
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- * Group I (negative control group): Root canals were not treated after cleaning and shaping. * Group II (positive control group): Root canals were treated with calcium hydroxide paste * Group III: Root canals were treated with CIP paste conventionally used by the dentist which was formed by mixing CIP with saline to form a paste. * Group IV: Root canals were treated with (F1) which is the prepared in-situ gel formulation containing CIP loaded chitosan coated PLGA nanoparticles. * Group V: Root canals were treated with (F2) which is the prepared in-situ gel containing ciprofloxacin hydrochloride.
| Arm | Type | Receives |
|---|---|---|
| Paste and solution of ciprofloxacin as Conventional Treatment | Experimental | Device: Ciprofloxacin paste and solutionPaste and solution of ciprofloxacin as conventional dosage forms and drugs used to treat endodontics infections. For ciprofloxacin solution is used once daily while the paste form used weekly. |
| Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel | Experimental | Device: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gelsChitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel dosage forms treat endodontics infections |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Root canal filled single rooted teeth with post treatment disease manifested by one or more of the following signs and symptoms:
- History of recurrent acute and/or chronic periapical abscess
- Pain on palpation and/or percussion at least after one month of previous procedure
- Radiographic evidence of bone loss either as a new developing lesion or an increase in the size of a pre-existing one.
Key exclusion criteria (4 listed)
- Teeth that were badly broken down indicated for extraction or with difficult isolation
- Immuno-compromised patients.
- Patients with history of taking antibiotics orally.
- Periodontally affected teeth.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gelsAlso: Chitosan Coated PLGA nanoparticles, PLGA nanoparticles as smart gelsantibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction. | Device | Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel |
| Ciprofloxacin paste and solutionConventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection | Device | Paste and solution of ciprofloxacin as Conventional Treatment |
Primary outcome
Determination of Bacterial count by counting bacterial colonies of the sample
Time frame: One week
Bacterial count was expected to be decreased by counting bacterial colonies of the sample after treatment and comparing with control without treatment
1 secondary outcome
Determination of the Biofilm inhibition using crystal violet and microplate reader
Time frame: one week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2022.
- Individual participant dataSharing planned: No
Related trials for Bacterial Infections Oral
Not yet recruitingPhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter
RecruitingObservational study
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
Not yet recruitingPhase 4
Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis
Tinea Corporis,Tinea Cruris,Tinea Faciei
Not yet recruitingPhase 1
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
Clostridium Difficile Infection
Not yet recruitingPhase 4
Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma
Survival of Flies Developing in Faecal Samples
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mona Arafa, Professor principal investigator
British University In Egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels and Ciprofloxacin paste and solution in people with Bacterial Infections Oral, run by British University In Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determination of Bacterial count by counting bacterial colonies of the sample (time frame: One week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2022.